Aratana Therapeutics, Inc. Net Income per Employee (PETX), current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket
 


Aratana Therapeutics, Inc.  (PETX)
 

Aratana Therapeutics Net Income per Employee

PETX's Quarterly Results, Trends, Rankings, Statistics
Aratana Therapeutics, Inc. recorded a cumulative net loss of $-13 million during 12 month ending in the first quarter 2019.
The Healthcare sector has seen employees of 132 other companies achieving higher income per employee. While Aratana Therapeutics's total ranking has deteriorated compared to the previous quarter from 0 to 3653.


What is Income per Employee Ratio?






PETX Net Income per Employee (Mar 31 2019)
I. Quarter
(Dec 31 2018)
IV. Quarter
(Sep 30 2018)
III. Quarter
(Jun 30 2018)
II. Quarter
(Mar 31 2018)
I. Quarter
Y / Y Net Income Change - - - - -
Net Income per Employee (TTM) $ -212,475 -241,344 -355,508 -646,541 -712,230
PETX's Total Ranking # 3653 # 0 # 0 # 0 # 0
Seq. Net Income Change - - - - -


PETX Net Income per Employee Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 133
Healthcare Sector # 401
Overall Market # 3653

Net Income per Employee Statistics
High Average Low
$ 1,157,623 $ -427,986 $ -1,530,279
(Mar 31 2014)   (Mar 31 2016)







Companies with similar Income per Employee for 12 month ending Mar 31 2019, within Healthcare Sector Income per Employee Income 12 month ending Mar 31 2019Number of Employees Mar 31 2019


Date modified: 2026-08-29T17:20:13+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.